| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
91,540,000 |
| Market
Cap: |
34.79(M) |
| Last
Volume: |
1,296,467 |
Avg
Vol: |
1,292,915 |
| 52
Week Range: |
$0.38 - $0.87 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Curis is a biotechnology company focused on the development of therapeutics for the treatment of cancer. Co.'s clinical stage drug candidates are: Emavusertib, which is being tested in a Phase 1/2 dose escalating clinical trial in patients with non-Hodgkin lymphomas; CI-8993, which is a monoclonal antibody; Fimepinostat, which is a small molecule that potently inhibits the activity of histone deacetylase, and phosphotidyl-inositol 3 kinase; CA-170, for which Co. has announced initial data from a clinical study in patients with mesothelioma in conjunction with the Society of lmmunotherapy of Cancer; and CA-327, which is a small molecule antagonist of PDL1 and TIM3.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Passeri Daniel R |
President and CEO |
• – – |
2004-01-07 |
4 |
S |
$5.01 |
$149,692 |
D/D |
(29,478) |
18,900 |
|
- |
|
| Passeri Daniel R |
President and CEO |
• – – |
2004-01-06 |
4 |
S |
$5.00 |
$19,191 |
D/D |
(3,822) |
48,378 |
|
- |
|
| Passeri Daniel R |
President and CEO |
• – – |
2004-01-05 |
4 |
S |
$5.00 |
$890 |
D/D |
(178) |
0 |
|
- |
|
| Rubin Lee L |
Senior Vice President,Research |
• – – |
2004-01-02 |
4 |
S |
$4.50 |
$45,000 |
D/D |
(10,000) |
9,814 |
|
- |
|
| Rubin Lee L |
Senior Vice President,Research |
• – – |
2004-01-02 |
4 |
OE |
$1.09 |
$10,900 |
D/D |
10,000 |
0 |
|
- |
|
| Missling Christopher U |
SVP, Finance and CFO |
• – – |
2003-11-21 |
4 |
S |
$5.04 |
$50,400 |
D/D |
(10,000) |
0 |
|
- |
|
| Missling Christopher U |
SVP, Finance and CFO |
• – – |
2003-11-20 |
4 |
S |
$5.15 |
$25,750 |
D/D |
(5,000) |
0 |
|
- |
|
| Mcnab James R |
Director |
– • – |
2003-11-14 |
4 |
S |
$5.22 |
$77,843 |
D/D |
(14,660) |
729,347 |
|
- |
|
| Mcnab James R |
Director |
– • – |
2003-11-14 |
4 |
S |
$5.28 |
$187,500 |
D/D |
(35,040) |
744,007 |
|
- |
|
| Mcnab James R |
Director |
– • – |
2003-11-10 |
4 |
S |
$4.96 |
$19,882 |
I/I |
(4,000) |
70,000 |
|
- |
|
| Mcnab James R |
Director |
– • – |
2003-11-07 |
4 |
S |
$4.77 |
$46,905 |
I/I |
(9,788) |
100,000 |
|
- |
|
| Mcnab James R |
Director |
– • – |
2003-11-07 |
4 |
S |
$4.77 |
$114,483 |
D/D |
(23,881) |
779,347 |
|
- |
|
| Mcnab James R |
Director |
– • – |
2003-11-06 |
4 |
S |
$4.76 |
$87,938 |
D/D |
(18,400) |
893,228 |
|
- |
|
| Mcnab James R |
Director |
– • – |
2003-11-05 |
4 |
S |
$4.68 |
$94,742 |
D/D |
(20,200) |
911,628 |
|
- |
|
| Bayh Susan B |
Director |
– • – |
2003-09-18 |
4 |
S |
$5.30 |
$26,500 |
I/I |
(5,000) |
1,000 |
|
- |
|
| Bayh Susan B |
Director |
– • – |
2003-09-18 |
4 |
S |
$5.05 |
$397,527 |
D/D |
(77,138) |
0 |
|
- |
|
| Bayh Susan B |
Director |
– • – |
2003-09-17 |
4 |
S |
$5.10 |
$5,100 |
I/I |
(1,000) |
1,000 |
|
- |
|
| Bayh Susan B |
Director |
– • – |
2003-09-17 |
4 |
S |
$5.00 |
$61,050 |
D/D |
(12,000) |
0 |
|
- |
|
| Bayh Susan B |
Director |
– • – |
2003-09-15 |
4/A |
S |
$5.10 |
$25,500 |
I/I |
(5,000) |
1,000 |
|
- |
|
| Bayh Susan B |
Director |
– • – |
2003-09-15 |
4/A |
S |
$5.00 |
$118,960 |
D/D |
(23,612) |
0 |
|
- |
|
| Bayh Susan B |
Director |
– • – |
2003-09-15 |
4 |
S |
$5.00 |
$75,718 |
D/D |
(15,138) |
0 |
|
- |
|
| Mcnab James R |
Director |
– • – |
2003-09-03 |
4 |
S |
$3.66 |
$183,080 |
D/D |
(50,000) |
931,828 |
|
- |
|
| Passeri Daniel R |
officerTitle |
• • – |
2003-09-02 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
52,378 |
|
- |
|
| Mcnab James R |
Director |
– • – |
2003-06-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
12,000 |
0 |
|
- |
|
| Potthoff Mary Elizabeth |
Vice President,General Counsel |
• – – |
2003-01-16 |
4 |
S |
$6.25 |
$31,250 |
D/D |
(5,000) |
0 |
|
- |
|
303 Records found
|
|
Page 12 of 13 |
|
|
